2017 update on pain management in patients with chronic kidney disease

Phuong Chi Pham, Kathy Khaing, Theodore M Sievers, Phuong Mai Pham, Jeffrey M Miller, Son V Pham, Phuong Anh Pham, Phuong Thu Pham, Phuong Chi Pham, Kathy Khaing, Theodore M Sievers, Phuong Mai Pham, Jeffrey M Miller, Son V Pham, Phuong Anh Pham, Phuong Thu Pham

Abstract

The prevalence of pain has been reported to be >60-70% among patients with advanced and end-stage kidney disease. Although the underlying etiologies of pain may vary, pain per se has been linked to lower quality of life and depression. The latter is of great concern given its known association with reduced survival among patients with end-stage kidney disease. We herein discuss and update the management of pain in patients with chronic kidney disease with and without requirement for renal replacement therapy with the focus on optimizing pain control while minimizing therapy-induced complications.

Keywords: CKD,; NSAIDS,; dialysis,; kidney transplantation,; opioids,; pain.

References

    1. Nahin RL. Estimates of pain prevalence and severity in adults: United States, 2012. J Pain 2015; 16: 769–780
    1. Opioid Prescriptions Dispensed by US Retail Pharmacies. IMS Health, Vector One: National Prescription Audit, Years 1997–2013 (13 July 2017, date last accessed).
    1. Davison SN, Koncicki H, Brennan F.. Pain in chronic kidney disease: a scoping review. Semin Dial 2014; 27: 188–204
    1. Pham PC, Toscano E, Pham PT. et al. Pain management in patients with chronic kidney disease. Nephrol Dialy Transpl Plus 2009; 2: 111–118
    1. Chapman CR, Nakamura Y.. A passion of the soul: an introduction to pain for consciousness researchers. Conscious Cogn 1999; 8: 391–422
    1. Berry PH, Covington EC, Dahl J, Katz JA, Miaskowski C.. Pain: Current Understanding of Assessment, Management, and Treatments, (13 July 2017, date last accessed).
    1. Rang HP, Bevan S, Dray A.. Chemical activation of nociceptive peripheral neurons. Br Med Bull 1991; 47: 534–538
    1. McHugh JM, McHugh WB.. Pain: neuroanatomy, chemical mediators and clinical implications. AACN Clin Issues 2000; 11: 168–178
    1. Woolf CJ. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med 2004; 140: 441–451
    1. Cline DM. Chronic pain: evaluation and treatment in the emergency department In: Greenfield RH. (ed). Managing Pain and End-of-Life Issues. Atlanta: AHC Media, 2007, 67–84
    1. Portenoy RK, Ahmed E.. Principles of opioid use in cancer pain. J Clin Onc 2014; 32(16): 1662–1670
    1. Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, Hansson P, Hughes R, Nurmikko T, Serra J.. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurol 2008; 70: 1630–1635
    1. Ferreira SH. The role of interleukins and nitric oxide in the mediation of inflammatory pain and its control by peripheral analgesics. Drugs 1993; 46: 1–9
    1. Finnerup NB. A review of central neuropathic pain states. Curr Opin Anaesthesiol 2008; 21: 586–589
    1. McMahon SB. Mechanisms of sympathetic pain. Br Med Bull 1991; 47: 584–600
    1. Dworkin RH, Jensen MP, Gammaitoni AR. et al. Symptom profiles differ in patients with neuropathic versus non-neuropathic pain. J Pain 2007; 8: 118–126
    1. Sheeler RD, Garza I, Vargas BB. et al. Chronic daily headache: ten steps for primary care providers to regain control. Headache 2016; 56: 1675–1684
    1. Schneiderhan J, Orizondo C.. Chronic pain: how to approach these 3 common conditions. J Fam Pract 2017; 66: 145–157
    1. Desai MJ, Saini V, Saini S.. Myofascial pain syndrome: a treatment review. Pain Ther 2013; 2: 21–36
    1. Harrison RA, Field TS.. Post stroke pain: identification, assessment, and therapy. Cerebrovasc Dis 2015; 39: 190–201
    1. Subedi B, Grossberg GT.. Phantom limb pain: mechanisms and treatment approaches. Pain Res Treat 2011; 2011: 864605.
    1. Finnerup NB, Attal N, Haroutounian S. et al. Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations. Lancet Neurol 2015; 14: 162–173
    1. Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain 1975; 1: 277–299
    1. Wong DL, Baker CM.. Pain in children: comparison of assessment scales. Pediatr Nurs 1988; 14: 9–17
    1. World Health Organization. Cancer Pain Relief: With a Guide to Opioid Availability, 2nd edn Geneva: World Health Organization, 1996, 3–36
    1. Murtagh EM, Chai MO, Donohoe P. et al. The use of opioid analgesia in end-stage renal disease patients managed without dialysis: recommendations for practice. J Pain Palliative Care Pharmacother 2007; 21: 5–16
    1. Goldberg RJ, Katz J.. A meta-analysis of the analgesic effects of omega-3 polyunsaturated fatty acid supplementation for inflammatory joint pain. Pain 2007; 129: 210–223
    1. Senftleber NK,, Nielsen SM, Andersen JR. et al. Marine oil supplements for arthritis pain: a systematic review and meta-analysis of randomized trials. Nutrients 2017; 9: E42.
    1. Gralow J, Tripathy D.. Managing metastatic bone pain: the role of bisphosphonates. J Pain Symptom Manage 2007; 33: 462–472
    1. Ciolek JJ. Cryotherapy. Review of physiological effects and clinical application. Cleve Clin Q 1985; 52: 65–68
    1. Collins NC. Is ice right? Does cryotherapy improve outcome for acute soft tissue injury? Emerg Med J 2008; 25: 409–429
    1. Adams ML, Arminio GJ.. Non-pharmacologic pain management intervention. Clin Podiatr Med Surg 2008; 10: 492–499
    1. DeSantana JM, Walsh DM, Vance C. et al. Effectiveness of transcutaneous electrical nerve stimulation for treatment of hyperalgesia and pain. Curr Rheum Rep 2008; 10: 492–499
    1. Hurlow A,, Bennet MI,, Robb KA. et al. Transcutaneous electric nerve stimulation (TENS) for cancer pain in adults. Cochrane Database Syst Rev 2012; 3: CD006276
    1. Mulvey MR,, Bagnall AM,, Johnson MI. et al. Transcutaneous electrical nerve stimulation (TENS) for phantom pain and stump pain following amputation in adults. Cochrane Database Syst Rev 2010; 5: CD007264
    1. Johnson MI,, Paley CA,, Howe TE. et al. Transcutaneous electrical nerve stimulation for acute pain. Cochrane Database Syst Rev 2015; 6: CD006142
    1. Gam AN, Johannsen F.. Ultrasound therapy in musculoskeletal disorders: a meta-analysis. Pain 1995; 63: 85–91
    1. Ramachadran VS, Rogers-Ramachandran D.. Synaesthesia in phantom limbs induced with mirrors. Proc R Soc B 1996; 263: 377–386
    1. Qaseem A, Wilt TJ, McLean RM, Forciea MA.. Noninvasive treatments for acute, subacute, and chronic low back pain: A clinical practice guideline from the American College of Physicians. Ann Intern Med 2017; 166: 514–530
    1. McAlindon TE, Bannuru RR, Sullivan RC. et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarth Cartilage 2014; 22: 363–388
    1. Kamarzarian A, Pham PMT, Pham PTT. et al. Pharmacology In: Pham P-C, Pham P-T (eds). Nephrology and Hypertension Board Review. Philadelphia, PA: Wolters Kluwer, 2016, pp. 334–354
    1. Pham PC, Deshmukh MS, Nast CC.. Tubular, interstitial, and cystic disorders In: Pham PC, Pham PT (eds). Nephrology and Hypertension Board Review. Philadelphia: Wolters Kluwer, 2016, pp. 185–201
    1. Aljadhey H, Tu W, Hansen RA. et al. Comparative effects on non-steroidal anti-inflammatory drugs (NSAIDS) on blood pressure in patients with hypertension. BMC Cardiovasc Disord 2012; 12: 93.
    1. Stillman MT, Schlesinger PA.. Nonsteroial anti-inflammatory drug nephrotoxicity: should we be concerned? Arch Intern Med 1990; 150: 268–270
    1. Dominkus M, Nicolakis M, Kotz R. et al. Comparison of tissue and plasma levels of ibuprofen after oral and topical administration. Arzneimittelforschung 1996; 46: 1138–1143
    1. Argoff CE. Topical analgesics in the management of acute and chronic pain. Mayo Clin Proc 2013; 88: 195–205
    1. Andrews PA, Sampson SA.. Topical non-steroidal drugs are systemically absorbed and may cause renal disease. Nephrol Dial Transplant 1999; 14: 187–189
    1. Harris RC, Breyer MD.. Update on cyclooxygenase-2 inhibitors. Clin J Am Soc Nephrol 2006; 1: 236–245
    1. Beakley BD, Kaye AM, Kaye AD.. Tramadol, pharmacology, side effects, and serotonin syndrome: a review. Pain Phys 2015; 18: 395–400
    1. Reeves RR, Burke RS.. Tramadol: basic pharmacology and emerging concepts. Drugs Today 2008; 44: 827–836
    1. Grond S, Sablotzki A.. Clinical pharmacology of tramadol. Clin Pharmacokinet 2004; 43: 879–923
    1. Lee CR, McTavish D, Sorkin EM.. Tramadol: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states. Drugs 1993; 46: 313–340
    1. Raffa RB, Friderichs E, Reimann W. et al. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an ‘atypical’ opioid analgesic. J Pharmacol Exp Ther 1992; 260: 275–285
    1. Tramadol ER - FDA prescribing information, side effects and uses. Par Pharmaceutical, Inc. 2017;
    1. Kurella M, Bennett WM, Chertow GM.. Analgesia in patients with ESRD: a review of available evidence. Am J Kidney Dis 2003; 42: 217–228
    1. Saboory E, Derchansky M, Ismaili M. et al. Mechanisms of morphine enhancement of spontaneous seizure activity. Anesth Analg 2007; 105: 1729–1735
    1. Davies G, Kingswood C, Street M.. Pharmacokinetics of opioids in renal dysfunction. Clin Pharmacol Kinet 1996; 31: 410–422
    1. Labroo RB, Paine MF, Thummel KE. et al. Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions. Drug Metab Dispos 1997; 25: 1072–1080
    1. Ayanga D, Shorter D, Kosten TR.. Update on pharmacotherapy for treatment of opioid use disorder. Expert Opin Pharmacother 2016; 17: 2307–2318
    1. Momeni M, Crucitti M, De Kock M.. Patient-controlled analgesia in the management of postoperative pain. Drugs 2006; 66: 2321–2237
    1. Felden L, Walter C, Harder S. et al. Comparative clinical effects of hydromorphone and morphine a meta-analysis. Br J Anaesth 2011; 107: 319–328
    1. McMillan SC. Assessing and managing opiate-induced constipation in adults with cancer. Cancer Control 2004; 11: 3–9
    1. Anantharamu T, Sharma S, Gupta AK. et al. Naloxegol: first oral peripherally acting mu opioid receptor antagonists for opioid-induced constipation. J Pharmacol Pharmacother 2015; 6: 188–192
    1. Dowell D, Haegerich TM, Chou R.. CDC guideline for prescribing opioids for chronic pain—United States, 2016. JAMA 2016; 315: 1624–1645

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj